Authors: Tiedemann L, Gorantla SP, Ahlf P, Schmidt LS, Pott C, Litterst M, Waetzig V, Nagel I, Ruemenapp J, von Bubnoff N, Cascorbi I, Kaehler M.
DOI: 10.3389/fcell.2025.1725857
Abstract Summary
Fibronectin 1 (FN1) emerges as a key player in chronic myeloid leukemia treatment resistance. Researchers found that FN1 levels drop significantly in TKI-resistant CML cells, and restoring FN1 expression re-sensitizes resistant cells to therapy. This discovery offers promise for overcoming the 25% treatment failure rate in CML patients and positions FN1 as both a potential therapeutic target and biomarker.
Why Brain? ðŸ§
FN1 protein downregulation linked to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Restoring FN1 expression re-sensitizes resistant cells to treatment, suggesting FN1 as potential biomarker.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
